Govt mulls extension for pharma new manufacturing practice norms to bail out small firms
Low compliance by the country’s 8,500 small and medium enterprises (MSMEs) manufacturing pharmaceuticals would raise the risk of plant closures and disruptions across India’s $50 billion pharmaceutical sector, a major global supplier of generic medicines.
Low compliance by the country’s 8,500 small and medium enterprises (MSMEs) manufacturing pharmaceuticals would raise the risk of plant closures and disruptions across India’s $50 billion pharmaceutical sector, a major global supplier of generic medicines.
What's Your Reaction?
Economist Admin
Admin managing news updates, RSS feed curation, and PR content publishing. Focused on timely, accurate, and impactful information delivery.
